Akorn Midazolam Injection Recalled Due to Incomplete Stability Studies
Akorn, Inc. is recalling all lots of Midazolam Injection nationwide due to manufacturing practice deviations. The company ceased operations and could not complete stability studies to verify the drug's safety and efficacy.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a high-risk injectable drug where the manufacturer's closure prevented completion of required stability studies. While no illnesses have been reported, the inability to verify drug stability and efficacy for a sedative injectable represents a risk-of-harm situation meeting the Score 3 criterion.
Plain-English summary
Akorn, Inc. is recalling all lots of Midazolam Injection, USP 50 mg/10 mL (5 mg/mL) for intramuscular or intravenous use. The recall covers all lots and affects distributions nationwide in the USA and Puerto Rico.
The FDA has classified this as a Class II recall due to Good Manufacturing Practice (CGMP) deviations. Akorn ceased business operations and could no longer continue the stability studies required to verify that the medication maintains its intended safety and efficacy throughout its shelf life.
The recalled product
- Product
- Midazolam Injection, USP, 50 mg/10mL (5mg/mL), For Intramuscular or Intravenous Use Only, 10 mL vials, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · stability unverified
See all →- HighFluticasone Propionate Nasal Spray Recalled Due to Manufacturing Quality Concerns
FDA (Drugs) · 2023-06-07
- ModerateAkorn Recalls Cromolyn Sodium Ophthalmic Solution Over Stability Studies
FDA (Drugs) · 2023-06-07
- ModerateFerrous Sulfate Iron Supplement Drops Recalled for Manufacturing Stability Issues
FDA (Drugs) · 2023-06-07
- HighTrihexyphenidyl Hydrochloride Oral Solution Recalled for Unverified Stability
FDA (Drugs) · 2023-06-07
- HighNeomycin and Polymyxin B Eye Ointment Recalled for Incomplete Stability Studies
FDA (Drugs) · 2023-06-07